Novo Nordisk A/S (NVO)
NVO trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31. Converted from DKK at 6.7640 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | NVO on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Denmark |
| IPO year | Not reported by the screener |
| SEC CIK | 0000353278 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $45.7B |
| Net income | $15.1B |
| Operating income | $18.9B |
| Net margin | 33.1% |
| Operating margin | 41.3% |
| Revenue growth | +6.4% |
| Cash | $3.9B |
| Total assets | $80.3B |
| P/E (computed) | 12.2× |
| P/S (computed) | 4.0× |
Reported in DKK; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-02-04 |
| Cash and burn | 26.5B DKK cash; operating cash flow 29.8B DKK a quarter. | Report 2025-12-31 |
| Shares outstanding | 4,465,000,000 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte Statsautoriseret Revisionspartnerselskab, Copenhagen, Denmark | PCAOB Form AP 2026-03-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | 309.1B DKK | 102.4B DKK | 119.1B DKK | 26.5B DKK | 131.0B DKK | 309.1B DKK | 20-F 2026-02-04 |
| FY 2024 2024-12-31 | 290.4B DKK | 101.0B DKK | 121.0B DKK | 15.7B DKK | 102.8B DKK | 290.4B DKK | 20-F 2026-02-04 |
| FY 2023 2023-12-31 | 232.3B DKK | 83.7B DKK | 108.9B DKK | 14.4B DKK | 27.0B DKK | 232.3B DKK | 20-F 2026-02-04 |
| FY 2022 2022-12-31 | 177.0B DKK | 55.5B DKK | 78.9B DKK | 12.7B DKK | 25.8B DKK | 177.0B DKK | 20-F 2025-02-05 |
| FY 2021 2021-12-31 | 140.8B DKK | 47.8B DKK | 55.0B DKK | 10.7B DKK | 26.6B DKK | 140.8B DKK | 20-F 2024-01-31 |
| FY 2020 2020-12-31 | 126.9B DKK | 42.1B DKK | 52.0B DKK | 12.2B DKK | 10.4B DKK | 126.9B DKK | 20-F 2023-02-01 |
| FY 2019 2019-12-31 | 122.0B DKK | 39.0B DKK | 46.8B DKK | 15.4B DKK | 4.5B DKK | 122.0B DKK | 20-F 2022-02-02 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in DKK.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 20-F | 2026-02-04 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.3% |
| 1 month | +9.4% |
| 3 months | -10.9% |
| Year to date | -18.2% |
| 1 year | -15.3% |
| From 52-week high | -34.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ABT | Abbott Laboratories | $107.45 | -0.99% | $186.1B |
| PFE | Pfizer Inc. | $28.86 | -0.10% | $164.5B |
| VRTX | Vertex Pharmaceuticals Incorporated | $537.79 | -0.15% | $136.4B |
| BMY | Bristol-Myers Squibb Company | $62.93 | -0.79% | $128.6B |
| AZN | AstraZeneca PLC | $184.02 | -0.23% | $285.4B |
| SNY | Sanofi ADS | $48.39 | +0.04% | $118.0B |
| NVS | Novartis AG | $160.20 | -0.19% | $305.7B |
| GSK | GSK plc | $50.41 | -0.08% | $102.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier